BioCentury
ARTICLE | Clinical News

Portola reports response rates for cerdulatinib

June 15, 2017 9:17 PM UTC

Portola Pharmaceuticals Inc. (NASDAQ:PTLA) reported interim data from a Phase IIa study of cerdulatinib (PRT062070) to treat relapsed or refractory B cell malignancies, and suggested it is still deciding whether to continue development in future studies of the dual inhibitor of spleen tyrosine kinase (SYK) and Janus kinase (JAK).

The new data showed that cerdulatinib led to 12 partial responses (PRs) among 18 patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). There were five PRs among nine patients with relapsed or refractory follicular lymphoma, and one PR among seven patients with other indolent non-Hodgkin's lymphoma (NHL) including marginal zone lymphoma and Waldenstrom's macroglobulinemia. Cerdulatinib led to a complete response in the first evaluable patient with relapsed or refractory peripheral T cell lymphoma (PTCL)...